ADCT:NYE-ADC Therapeutics SA (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.34

Change

+0.45 (+23.81)%

Market Cap

USD 0.14B

Volume

1.32M

Analyst Target

USD 53.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TECH Bio-Techne Corp

+0.13 (+0.26%)

USD 8.03B
BHVN Biohaven Pharmaceutical Holdin..

-0.27 (-1.69%)

USD 1.64B
RCUS Arcus Biosciences Inc

+0.15 (+1.75%)

USD 0.91B
NUVB Nuvation Bio Inc

+0.04 (+1.77%)

USD 0.77B
DNA Ginkgo Bioworks Holdings

+0.16 (+2.02%)

USD 0.46B
CYBN Cybin Inc

+0.78 (+11.61%)

USD 0.15B
PLX Protalix Biotherapeutics Inc

+0.01 (+0.60%)

USD 0.13B
OSTX OS Therapies Incorporated

-0.05 (-3.05%)

USD 0.07B
ANRO Alto Neuroscience, Inc.

+0.01 (+0.40%)

USD 0.07B
ATNM Actinium Pharmaceuticals Inc

+0.12 (+7.19%)

USD 0.05B

ETFs Containing ADCT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.59% 92% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.59% 92% A 91% A-
Trailing 12 Months  
Capital Gain -43.07% 66% D+ 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.07% 66% D+ 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.39% 27% F 4% F
Dividend Return -15.39% 27% F 4% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 97.90% 43% F 7% C-
Risk Adjusted Return -15.72% 41% F 15% F
Market Capitalization 0.14B 79% B- 31% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.